Trial Profile
A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2018
Price :
$35
*
At a glance
- Drugs Netarsudil (Primary) ; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Aerie Pharmaceuticals
- 02 Dec 2014 Primary endpoint has been met (mean intraocular pressure across subjects measured on each day at each post-treatment timepoint, excluding days 29 and 30), according to an Aerie Pharmaceuticals media release.
- 02 Dec 2014 Results published in an Aerie Pharmaceuticals media release.
- 26 Mar 2014 New trial record